

# Provincial Isotope Sector Briefing Newfoundland and Labrador



## Executive Summary



### State-of-the-art technology

State-of-the-art infrastructure and the largest radiopharmaceutical production facility in Atlantic Canada.



### Investing in the future of medical isotopes

Newfoundland and Labrador continues to invest in the future of medical isotopes through major expansions of its Nuclear and Molecular Medicine program.



### Education

Supporting future workforce development with research and course opportunities, and the development of robust academic and research partnerships to advance innovation in the field.

## Isotope Infrastructure

Newfoundland and Labrador Health Services (NLHS), is supported by state-of-the-art infrastructure and the largest radiopharmaceutical production facility in Atlantic Canada. NLHS is strengthening its leadership in precision health through a major expansion of its Nuclear and Molecular Medicine program.



**2 PET-CT**  
*located in St. John's*



**1 NEW PET-CT**  
*being added in Western NFL*



NLHS currently operates in St John's. The St. John's facility integrates diagnostic imaging, therapeutic radiopharmaceutical treatments, and research functions in one location, enhancing patient care and supporting rapid service innovation.

# Provincial Isotope Sector Briefing Newfoundland and Labrador

## Isotope Infrastructure

Newfoundland is also investing in future isotope development through recent government and organizational investments including:



**\$6 million in capital funding**





**\$3.5 million in increased operational funding**

supporting PET-CT expansion, therapeutic radiopharmaceutical programs, cyclotron operations, and enhanced research and training capacity

## Patient Access

Newfoundland is expanding its radiopharmaceutical production through its Radiopharmaceutical Sciences team. The Radiopharmaceutical Sciences team has achieved several significant production milestones:

**8,887** patients   
supported by **700 productions** of 18F-FDG  
*Onsite production commenced Nov 26 2020*

**490** patients   
utilized 191 preparations of 68Ga-DOTATATE  
*Commenced Oct 17 2022*

**166** patients  
utilized 46 preparations of 68Ga-PSMA  
*Commenced Feb 19 2025*



**Lutathera Therapy**  
as of December 2025, **14 patients treated**  
*Commenced May 24 2023*

**20** patients  
treated with Radium-223 therapy  
*Commenced March 19 2020*



**Pluvicto Therapy**  
as of December 2025, **9 patients treated**  
*Commenced August 29 2025*

**500** patients  
forecasted annually for [13N]Ammonia  
*Commencement estimated for Fall 2026*

The facility also reached the following milestones:



Facility reached its **700<sup>th</sup> F-18** production



Facility reached its **191<sup>st</sup> Gallium DOTATATE** preparation



Newfoundland Health Services celebrated **five years** of FDG production.

# Provincial Isotope Sector Briefing Newfoundland and Labrador

## Workforce Development and Education

NLHS is working closely with academic partners across Atlantic Canada to strengthen the future workforce:

**Memorial University** – supporting and developing education in medical physics, health physics, and nuclear medicine through hands-on training and new curriculum initiatives.

**Dalhousie University** – providing funded academic seats, including a reserved Nuclear Medicine seat for NL students, and practicum placements within NLHS.



The department is supported by a team of 43 experts, including nuclear medicine physicians, medical physicists, technologists, radiopharmaceutical scientists, research nurses, and quality and safety specialists.

## Clinical Trials



NL collaborates with the Atlantic Clinical Trials Network (ACTN), a pan-Atlantic initiative working to strengthen and accelerate clinical research across Eastern Canada. ACTN brings together academic institutions, health authorities, and research organizations from several Atlantic provinces including Nova Scotia, New Brunswick, Prince Edward Island, and Newfoundland and Labrador.

NLHS is broadening its national research profile through:

- Collaboration with the Canadian Cancer Trials Group (CCTG)
- Partnerships with pharmaceutical companies for clinical trials in diagnostic and therapeutic radiopharmaceuticals
- Development of a new Preclinical Animal Imaging Suite (SAIF), enabling advanced research in cancer, neurology, immunology, cardiovascular disease, and drug development

These initiatives support evidence-based medicine, improve access to innovative treatments, and promote scientific discovery within the province.

## References

[Atlantic Clinical Trials Network \(ACTN\) - N2 Canada](#)

[Cyclotron and processing facility - Medical Imaging](#)

[Discipline of Radiology | Radiology | Memorial University of Newfoundland](#)

[Nuclear and Molecular Medicine facility - Eastern Health](#)

[Provincial Government Adding Two New PET-CT Scanners to Hospitals in Newfoundland and Labrador - News Releases](#)